Please assess the completion status of the following clinical trial:

Trial Title: 4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed. Where relevant, a legal representative will also sign the informed consent according to local laws and regulations.~2. Subjects who complete Week 52 of study CAIN457A2304 or complete Week 40 of study CAIN457A2307~3. Subjects expected to benefit from participation in the extension study, as assessed by the subject and investigator~Exclusion Criteria:~1. A protocol deviation in the core studies which according to the investigator will prevent the meaningful analysis of the extension study for the individual subject~2. Ongoing use of prohibited psoriasis or non-psoriasis treatments. Time period from last use of prohibited treatments in the core study to first dose of study drug in this extension study.~3. Subjects expected to be exposed to an undue safety risk if participating in the trial~4. Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial~5. Plans for administration of live vaccines during the study period~6. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\>10 mIU/mL).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AIN457 150 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 1 s.c. Secukinumab 150 mg Pre-filled seringue (PFS) injection + 1 s.c. Placebo (PBO) Secukinumab PFS injection every 4 weeks
- AIN457 150 mg - Start of relapse (SoR) (Type: EXPERIMENTAL): Start of relapse: 1 s.c. Secukinumab 150 mg PFS injection + 1 s.c. PBO Secukinumab PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks
- AIN457 300 mg - Fixed Interval (FI) (Type: EXPERIMENTAL): 2 s.c. Secukinumab 150 mg PFS injections every 4 weeks
- AIN457 300 mg - Start of Relapse (SoR) (Type: EXPERIMENTAL): Start of relapse: 2 s.c. Secukinumab 150 mg PFS injection every 4 weeks~Otherwise: 2 s.c. PBO Secukinumab PFS injections every 4 weeks
- AIN457 300 mg - Open Label (OL) (Type: EXPERIMENTAL): Open Label - Secukinumab 300mg every 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).